Less than two months after Kailera Therapeutics Inc. made headlines with biopharma’s largest IPO to date, Parabilis Medicines Inc. has come along and surpassed it. The oncology-focused firm priced its ...

Scientists at Columbia University have used base editing to make precise changes in the genomes of human embryos, avoiding the damage to chromosomes that occurs following two-stranded DNA cuts with ...

Shares of Nuvalent Inc. (NASDAQ:NUVL) were trading at $122.82, up $34.33, or 38%, on word that GSK plc is paying $10.6 billion to take over the firm. Specifically, London-based GSK is offering to ...

In its largest acquisition to date, Incyte Inc. snagged rights to phase III-stage VGA-039, a monoclonal antibody the firm ...

City Therapeutics Inc. has completed a $99.5 million series B financing to support its pipeline of RNA interference (RNAi) therapeutics and accelerate its next-generation RNAi engineering platform.

Innovent Biologics Co. Ltd.’s Claudin18.2-targeted antibody-drug conjugate (ADC), arcotatug tavatecan (IBI-343, TAK-921), met the primary endpoint in the international multicenter phase III G-Hope-001 ...

Harness Therapeutics Ltd. has been awarded a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to advance its Parkinson’s disease program targeting glucocerebrosidase (GCase) ...

At the recent American Diabetes Association meeting, researchers from Century Therapeutics Inc. presented preclinical efficacy data on CNTY-813, an induced pluripotent stem cell (iPSC)-derived cell ...

Clinical updates for biopharma and med tech, including data readouts and publications: Aim, Altesa, Amgen, Antag, Astrazeneca, Biomea, Boehringer, Corcept, Curasight ...

Gen1e Lifesciences Inc. has obtained both orphan drug and rare pediatric disease designations from the U.S. FDA for GEn-1123 for the treatment of Duchenne muscular dystrophy (DMD).

Ahead of an approval bid with its own candidate in non-small-cell lung cancer, GSK plc is planting a stake in the space by way of the $10.6 billion buyout of Nuvalent Inc. for $124 per share, a 40% ...

Dexcom Inc. and Insulet Corp. reported new clinical trial data on their diabetes technologies at the 2026 Scientific Sessions of the American Diabetes Association in New Orleans, offering insights ...